Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
FibroGen receives rare pediatric disease designation from FDA for pamrevlumab » 07:04
04/15/21
04/15
07:04
04/15/21
07:04
FGEN

FibroGen

$19.23 /

-0.505 (-2.56%)

FibroGen announced that…

FibroGen announced that the Food and Drug Administration has granted Rare Pediatric Disease Designation for the company's anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy, or DMD. Pamrevlumab has also received Fast Track designation from the FDA and is currently being evaluated in two Phase 3 trials for the treatment of DMD.

ShowHide Related Items >><<
FGEN FibroGen
$19.23 /

-0.505 (-2.56%)

FGEN FibroGen
$19.23 /

-0.505 (-2.56%)

04/07/21
Fly Intel: Top five analyst downgrades
04/07/21 Mizuho
Mizuho downgrades FibroGen to Neutral on 'higher risk and uncertainty'
04/07/21 Mizuho
FibroGen downgraded to Neutral from Buy at Mizuho
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
FGEN FibroGen
$19.23 /

-0.505 (-2.56%)

FGEN FibroGen
$19.23 /

-0.505 (-2.56%)

Over a week ago
Hot Stocks
FibroGen receives fast track designation from FDA for pamrevlumab » 07:02
04/12/21
04/12
07:02
04/12/21
07:02
FGEN

FibroGen

$18.59 /

-0.2 (-1.06%)

FibroGen announced that…

FibroGen announced that the Food and Drug Administration has granted Fast Track designation for the company's anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy, or DMD. This designation follows review of the Phase 2 clinical data from a single-arm trial in non-ambulatory patients with DMD, and represents recognition by the FDA that pamrevlumab has the potential to address an unmet medical need for this disease. Pamrevlumab is currently being evaluated in two Phase 3 trials for the treatment of DMD.

ShowHide Related Items >><<
FGEN FibroGen
$18.59 /

-0.2 (-1.06%)

FGEN FibroGen
$18.59 /

-0.2 (-1.06%)

04/07/21
Fly Intel: Top five analyst downgrades
04/07/21 Mizuho
Mizuho downgrades FibroGen to Neutral on 'higher risk and uncertainty'
04/07/21 Mizuho
FibroGen downgraded to Neutral from Buy at Mizuho
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
FGEN FibroGen
$18.59 /

-0.2 (-1.06%)

FGEN FibroGen
$18.59 /

-0.2 (-1.06%)

FGEN FibroGen
$18.59 /

-0.2 (-1.06%)

On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:38
04/07/21
04/07
16:38
04/07/21
16:38
AMZN

Amazon.com

$3,280.07 /

+54.68 (+1.70%)

, CCL

Carnival

$28.99 /

+0.39 (+1.36%)

, CAHC

CA Healthcare Acquisition

$10.01 /

+0.36 (+3.73%)

, XOM

Exxon Mobil

$56.59 /

+0.25 (+0.44%)

, OUST

Ouster

$9.85 /

+2.02 (+25.80%)

, BHVN

Biohaven Pharmaceutical

$71.27 /

+5.67 (+8.64%)

, FGEN

FibroGen

$19.75 /

-14.87 (-42.95%)

, GEO

Geo Group

$6.21 /

-1.6 (-20.49%)

, AZN

AstraZeneca

$48.44 /

-0.78 (-1.58%)

Equities had a day of…

ShowHide Related Items >><<
XOM Exxon Mobil
$56.59 /

+0.25 (+0.44%)

OUST Ouster
$9.85 /

+2.02 (+25.80%)

GEO Geo Group
$6.21 /

-1.6 (-20.49%)

FGEN FibroGen
$19.75 /

-14.87 (-42.95%)

CCL Carnival
$28.99 /

+0.39 (+1.36%)

CAHC CA Healthcare Acquisition
$10.01 /

+0.36 (+3.73%)

BHVN Biohaven Pharmaceutical
$71.27 /

+5.67 (+8.64%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

AMZN Amazon.com
$3,280.07 /

+54.68 (+1.70%)

AMZN Amazon.com
$3,280.07 /

+54.68 (+1.70%)

04/05/21 Evercore ISI
Amazon.com assumed with an Outperform at Evercore ISI
04/01/21 Wedbush
Microsoft gets another major win within the beltway, says Wedbush
04/01/21 Credit Suisse
Ubiquiti price target lowered to $126 from $157 at Credit Suisse
03/31/21 Wolfe Research
Amazon.com assumed with an Outperform at Wolfe Research
CCL Carnival
$28.99 /

+0.39 (+1.36%)

04/08/21 Deutsche Bank
Carnival price target raised to $25 from $16 at Deutsche Bank
04/08/21 Stifel
Carnival price target raised to $35 from $30 at Stifel
04/07/21 William Blair
Carnival stock already pricing in recovery, says William Blair
04/01/21 Citi
Carnival initiated with a Buy at Citi
CAHC CA Healthcare Acquisition
$10.01 /

+0.36 (+3.73%)

XOM Exxon Mobil
$56.59 /

+0.25 (+0.44%)

04/06/21 Goldman Sachs
Chevron downgraded to Neutral from Buy at Goldman Sachs
03/08/21 UBS
Exxon Mobil price target raised to $59 from $48 at UBS
03/05/21 DZ Bank
Exxon Mobil upgraded to Hold from Sell at DZ Bank
03/04/21 MKM Partners
Exxon Mobil price target raised to $60 from $56 at MKM Partners
OUST Ouster
$9.85 /

+2.02 (+25.80%)

04/07/21 Citi
Ouster initiated with a Buy at Citi
BHVN Biohaven Pharmaceutical
$71.27 /

+5.67 (+8.64%)

04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
FGEN FibroGen
$19.75 /

-14.87 (-42.95%)

04/07/21
Fly Intel: Top five analyst downgrades
04/07/21 Mizuho
Mizuho downgrades FibroGen to Neutral on 'higher risk and uncertainty'
04/07/21 Mizuho
FibroGen downgraded to Neutral from Buy at Mizuho
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
GEO Geo Group
$6.21 /

-1.6 (-20.49%)

06/29/20 Noble Capital
Geo Group initiated with an Outperform at Noble Capital
AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
XOM Exxon Mobil
$56.59 /

+0.25 (+0.44%)

GEO Geo Group
$6.21 /

-1.6 (-20.49%)

FGEN FibroGen
$19.75 /

-14.87 (-42.95%)

CCL Carnival
$28.99 /

+0.39 (+1.36%)

BHVN Biohaven Pharmaceutical
$71.27 /

+5.67 (+8.64%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

AMZN Amazon.com
$3,280.07 /

+54.68 (+1.70%)

  • 16
    Mar
  • 23
    Feb
XOM Exxon Mobil
$56.59 /

+0.25 (+0.44%)

GEO Geo Group
$6.21 /

-1.6 (-20.49%)

CCL Carnival
$28.99 /

+0.39 (+1.36%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

AMZN Amazon.com
$3,280.07 /

+54.68 (+1.70%)

XOM Exxon Mobil
$56.59 /

+0.25 (+0.44%)

OUST Ouster
$9.85 /

+2.02 (+25.80%)

FGEN FibroGen
$19.75 /

-14.87 (-42.95%)

CCL Carnival
$28.99 /

+0.39 (+1.36%)

CAHC CA Healthcare Acquisition
$10.01 /

+0.36 (+3.73%)

BHVN Biohaven Pharmaceutical
$71.27 /

+5.67 (+8.64%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

AMZN Amazon.com
$3,280.07 /

+54.68 (+1.70%)

XOM Exxon Mobil
$56.59 /

+0.25 (+0.44%)

OUST Ouster
$9.85 /

+2.02 (+25.80%)

GEO Geo Group
$6.21 /

-1.6 (-20.49%)

FGEN FibroGen
$19.75 /

-14.87 (-42.95%)

CCL Carnival
$28.99 /

+0.39 (+1.36%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

AMZN Amazon.com
$3,280.07 /

+54.68 (+1.70%)

On The Fly
FibroGen slides after 'unfavorable disclosure' on safety data for anemia pill » 14:22
04/07/21
04/07
14:22
04/07/21
14:22
AZN

AstraZeneca

$48.43 /

-0.79 (-1.61%)

, GNHAY

Vifor Pharma

$0.00 /

+ (+0.00%)

, AKBA

Akebia

$3.27 /

+0.05 (+1.55%)

, FGEN

FibroGen

$20.91 /

-13.71 (-39.60%)

Shares of FibroGen (FGEN)…

ShowHide Related Items >><<
FGEN FibroGen
$20.91 /

-13.71 (-39.60%)

AZN AstraZeneca
$48.43 /

-0.79 (-1.61%)

AKBA Akebia
$3.27 /

+0.05 (+1.55%)

AZN AstraZeneca
$48.43 /

-0.79 (-1.61%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
GNHAY Vifor Pharma
$0.00 /

+ (+0.00%)

04/07/21 JPMorgan
Vifor Pharma upgraded to Neutral from Underweight at JPMorgan
03/29/21 UBS
Vifor Pharma price target raised to CHF 127 from CHF 119 at UBS
03/05/21 Credit Suisse
Vifor Pharma price target lowered to CHF 144 from CHF 149 at Credit Suisse
03/04/21 JPMorgan
Vifor Pharma price target lowered to CHF 120 from CHF 130 at JPMorgan
AKBA Akebia
$3.27 /

+0.05 (+1.55%)

04/07/21 Piper Sandler
Piper 'incrementally positive' on Akebia after 'surprising' FibroGen update
03/30/21 Piper Sandler
Piper likes setup for Akebia shares after vadadustat submission
03/08/21 Cantor Fitzgerald
Akebia initiated with an Overweight at Cantor Fitzgerald
03/08/21 H.C. Wainwright
Akebia price target lowered to $6 from $9 at H.C. Wainwright
FGEN FibroGen
$20.91 /

-13.71 (-39.60%)

04/07/21
Fly Intel: Top five analyst downgrades
04/07/21 Mizuho
Mizuho downgrades FibroGen to Neutral on 'higher risk and uncertainty'
04/07/21 Mizuho
FibroGen downgraded to Neutral from Buy at Mizuho
FGEN FibroGen
$20.91 /

-13.71 (-39.60%)

AZN AstraZeneca
$48.43 /

-0.79 (-1.61%)

AKBA Akebia
$3.27 /

+0.05 (+1.55%)

  • 12
    May
AZN AstraZeneca
$48.43 /

-0.79 (-1.61%)

AKBA Akebia
$3.27 /

+0.05 (+1.55%)

FGEN FibroGen
$20.91 /

-13.71 (-39.60%)

AZN AstraZeneca
$48.43 /

-0.79 (-1.61%)

AZN AstraZeneca
$48.43 /

-0.79 (-1.61%)

AKBA Akebia
$3.27 /

+0.05 (+1.55%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:26
04/07/21
04/07
12:26
04/07/21
12:26
AMZN

Amazon.com

$3,287.62 /

+62.23 (+1.93%)

, CCL

Carnival

$29.33 /

+0.73 (+2.55%)

, CAHC

CA Healthcare Acquisition

$10.05 /

+0.4 (+4.15%)

, OUST

Ouster

$9.75 /

+1.92 (+24.52%)

, BHVN

Biohaven Pharmaceutical

$72.25 /

+6.65 (+10.14%)

, FGEN

FibroGen

$20.86 /

-13.765 (-39.76%)

, GEO

Geo Group

$6.24 /

-1.57 (-20.10%)

Equity futures were…

ShowHide Related Items >><<
OUST Ouster
$9.75 /

+1.92 (+24.52%)

GEO Geo Group
$6.24 /

-1.57 (-20.10%)

FGEN FibroGen
$20.86 /

-13.765 (-39.76%)

CCL Carnival
$29.33 /

+0.73 (+2.55%)

CAHC CA Healthcare Acquisition
$10.05 /

+0.4 (+4.15%)

BHVN Biohaven Pharmaceutical
$72.25 /

+6.65 (+10.14%)

AMZN Amazon.com
$3,287.62 /

+62.23 (+1.93%)

AMZN Amazon.com
$3,287.62 /

+62.23 (+1.93%)

04/05/21 Evercore ISI
Amazon.com assumed with an Outperform at Evercore ISI
04/01/21 Wedbush
Microsoft gets another major win within the beltway, says Wedbush
04/01/21 Credit Suisse
Ubiquiti price target lowered to $126 from $157 at Credit Suisse
03/31/21 Wolfe Research
Amazon.com assumed with an Outperform at Wolfe Research
CCL Carnival
$29.33 /

+0.73 (+2.55%)

04/07/21 William Blair
Carnival stock already pricing in recovery, says William Blair
04/01/21 Citi
Carnival initiated with a Buy at Citi
03/24/21 Stifel
Cruiseline stock selloff 'unwarranted,' says Stifel
03/18/21
Fly Intel: Top five analyst upgrades
CAHC CA Healthcare Acquisition
$10.05 /

+0.4 (+4.15%)

OUST Ouster
$9.75 /

+1.92 (+24.52%)

04/07/21 Citi
Ouster initiated with a Buy at Citi
BHVN Biohaven Pharmaceutical
$72.25 /

+6.65 (+10.14%)

04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
FGEN FibroGen
$20.86 /

-13.765 (-39.76%)

04/07/21
Fly Intel: Top five analyst downgrades
04/07/21 Mizuho
Mizuho downgrades FibroGen to Neutral on 'higher risk and uncertainty'
04/07/21 Mizuho
FibroGen downgraded to Neutral from Buy at Mizuho
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
GEO Geo Group
$6.24 /

-1.57 (-20.10%)

06/29/20 Noble Capital
Geo Group initiated with an Outperform at Noble Capital
GEO Geo Group
$6.24 /

-1.57 (-20.10%)

FGEN FibroGen
$20.86 /

-13.765 (-39.76%)

CCL Carnival
$29.33 /

+0.73 (+2.55%)

BHVN Biohaven Pharmaceutical
$72.25 /

+6.65 (+10.14%)

AMZN Amazon.com
$3,287.62 /

+62.23 (+1.93%)

  • 16
    Mar
  • 23
    Feb
GEO Geo Group
$6.24 /

-1.57 (-20.10%)

CCL Carnival
$29.33 /

+0.73 (+2.55%)

AMZN Amazon.com
$3,287.62 /

+62.23 (+1.93%)

OUST Ouster
$9.75 /

+1.92 (+24.52%)

FGEN FibroGen
$20.86 /

-13.765 (-39.76%)

CCL Carnival
$29.33 /

+0.73 (+2.55%)

CAHC CA Healthcare Acquisition
$10.05 /

+0.4 (+4.15%)

BHVN Biohaven Pharmaceutical
$72.25 /

+6.65 (+10.14%)

AMZN Amazon.com
$3,287.62 /

+62.23 (+1.93%)

OUST Ouster
$9.75 /

+1.92 (+24.52%)

GEO Geo Group
$6.24 /

-1.57 (-20.10%)

FGEN FibroGen
$20.86 /

-13.765 (-39.76%)

CCL Carnival
$29.33 /

+0.73 (+2.55%)

AMZN Amazon.com
$3,287.62 /

+62.23 (+1.93%)

Downgrade
Fly Intel: Top five analyst downgrades » 09:56
04/07/21
04/07
09:56
04/07/21
09:56
FGEN

FibroGen

$22.36 /

-12.26 (-35.41%)

, CASY

Casey's General Stores

$216.65 /

-2.7 (-1.23%)

, ABCB

Ameris Bancorp

$52.44 /

-0.43 (-0.81%)

, BFAM

Bright Horizons

$169.03 /

-9.25 (-5.19%)

, SRE

Sempra Energy

$133.98 /

-0.25 (-0.19%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. FibroGen (FGEN) downgraded to Neutral from Buy at H.C. Wainwright and Mizuho. 2. Casey's General Stores (CASY) downgraded to Market Perform from Outperform at Raymond James with analyst Bobby Griffin saying the downgrade is not a reflection of Casey's recent operating performance or management's capabilities, but a factor of Casey's valuation versus its historical valuation and peers. 3. Ameris Bancorp (ABCB) downgraded to Outperform from Strong Buy at Raymond James with analyst David Feaster saying the downgrade is driven by its strong performance since September 2020. 4. Bright Horizons (BFAM) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Toni Kaplan saying the potential for changing on-site work dynamics and more employer flexibility post-pandemic could result in daycare becoming more local to employee homes and lead to increased competition for Bright Horizons. 5. Sempra Energy (SRE) downgraded to Neutral from Buy at Seaport Global with analyst Angie Storozynski saying the KKR (KKR) deal should make the IEnova stock tender more expensive, noting that market valuations of California utility peers are "sharply discounted." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
SRE Sempra Energy
$133.98 /

-0.25 (-0.19%)

FGEN FibroGen
$22.36 /

-12.26 (-35.41%)

CASY Casey's General Stores
$216.65 /

-2.7 (-1.23%)

BFAM Bright Horizons
$169.03 /

-9.25 (-5.19%)

ABCB Ameris Bancorp
$52.44 /

-0.43 (-0.81%)

FGEN FibroGen
$22.36 /

-12.26 (-35.41%)

04/07/21 Mizuho
Mizuho downgrades FibroGen to Neutral on 'higher risk and uncertainty'
04/07/21 Mizuho
FibroGen downgraded to Neutral from Buy at Mizuho
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
04/07/21 H.C. Wainwright
FibroGen downgraded to Neutral from Buy at H.C. Wainwright
CASY Casey's General Stores
$216.65 /

-2.7 (-1.23%)

04/07/21 Raymond James
Casey's General Stores downgraded to Market Perform at Raymond James
04/07/21 Raymond James
Casey's General Stores downgraded to Market Perform from Outperform at Raymond James
03/10/21 Raymond James
Casey's General Stores price target raised to $215 from $200 at Raymond James
03/10/21 Deutsche Bank
Casey's General Stores price target lowered to $217 from $220 at Deutsche Bank
ABCB Ameris Bancorp
$52.44 /

-0.43 (-0.81%)

04/07/21 Raymond James
Ameris Bancorp downgraded to Outperform from Strong Buy at Raymond James
03/30/21 DA Davidson
Ameris Bancorp downgraded to Neutral at DA Davidson on valuation
03/30/21 DA Davidson
Ameris Bancorp downgraded to Neutral from Buy at DA Davidson
03/08/21 Truist
Ameris Bancorp price target raised to $60 from $48 at Truist
BFAM Bright Horizons
$169.03 /

-9.25 (-5.19%)

04/07/21 Morgan Stanley
Morgan Stanley cuts Bright Horizons to Underweight on work flexibility risks
04/07/21 Morgan Stanley
Bright Horizons downgraded to Underweight from Equal Weight at Morgan Stanley
03/18/21 Jefferies
Bright Horizons price target raised to $215 from $210 at Jefferies
02/19/21 Barclays
Bright Horizons price target raised to $190 from $145 at Barclays
SRE Sempra Energy
$133.98 /

-0.25 (-0.19%)

04/07/21 Seaport Global
Seaport downgrades Sempra Energy to Neutral after 'good, not great' SIP deal
04/07/21 Seaport Global
Sempra Energy downgraded to Neutral from Buy at Seaport Global
04/06/21 BMO Capital
Sempra Energy price target raised to $147 from $142 at BMO Capital
01/14/21 Wells Fargo
Sempra Energy upgraded to Overweight from Equal Weight at Wells Fargo
SRE Sempra Energy
$133.98 /

-0.25 (-0.19%)

FGEN FibroGen
$22.36 /

-12.26 (-35.41%)

CASY Casey's General Stores
$216.65 /

-2.7 (-1.23%)

BFAM Bright Horizons
$169.03 /

-9.25 (-5.19%)

ABCB Ameris Bancorp
$52.44 /

-0.43 (-0.81%)

CASY Casey's General Stores
$216.65 /

-2.7 (-1.23%)

FGEN FibroGen
$22.36 /

-12.26 (-35.41%)

CASY Casey's General Stores
$216.65 /

-2.7 (-1.23%)

SRE Sempra Energy
$133.98 /

-0.25 (-0.19%)

FGEN FibroGen
$22.36 /

-12.26 (-35.41%)

On The Fly
Fly Intel: Pre-market Movers » 08:57
04/07/21
04/07
08:57
04/07/21
08:57
CAHC

CA Healthcare Acquisition

$9.65 /

+ (+0.00%)

, TMDX

TransMedics

$34.41 /

+0.1 (+0.29%)

, HYLN

Hyliion Holdings

$10.86 /

+0.11 (+1.02%)

, HIMX

Himax

$14.44 /

+0.25 (+1.76%)

, SMPL

Simply Good Foods

$31.21 /

-0.17 (-0.54%)

, MSM

MSC Industrial

$91.77 /

-0.065 (-0.07%)

, RPM

RPM

$94.30 /

+0.21 (+0.22%)

, FGEN

FibroGen

$34.61 /

-0.93 (-2.62%)

, FIXX

Homology Medicines

$9.30 /

-0.34 (-3.53%)

, UPST

Upstart

$143.99 /

+3.03 (+2.15%)

Check out this morning's…

ShowHide Related Items >><<
UPST Upstart
$143.99 /

+3.03 (+2.15%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

SMPL Simply Good Foods
$31.21 /

-0.17 (-0.54%)

RPM RPM
$94.30 /

+0.21 (+0.22%)

MSM MSC Industrial
$91.77 /

-0.065 (-0.07%)

HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

HIMX Himax
$14.44 /

+0.25 (+1.76%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

CAHC CA Healthcare Acquisition
$9.65 /

+ (+0.00%)

CAHC CA Healthcare Acquisition
$9.65 /

+ (+0.00%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

04/07/21 Canaccord
TransMedics label likely more limited than expected, says Canaccord
03/29/21 Cowen
TransMedics price target raised to $49 from $44 at Cowen
03/15/21 Canaccord
TransMedics price target raised to $79 from $46 at Canaccord
03/03/21 Morgan Stanley
TransMedics price target raised to $38 from $16 at Morgan Stanley
HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

03/18/21 UBS
Hyliion Holdings initiated with a Neutral at UBS
02/02/21 Goldman Sachs
Hyliion Holdings downgraded to Sell from Neutral at Goldman Sachs
12/16/20 Barclays
Hyliion Holdings initiated with an Overweight at Barclays
10/28/20
Fly Intel: Top five analyst initiations
HIMX Himax
$14.44 /

+0.25 (+1.76%)

03/09/21 Vertical Group
Himax reinstated with a Neutral at Vertical Group
02/08/21 Northland
Himax price target raised to $13 from $4.50 at Northland
01/27/21 Nomura
Himax upgraded to Buy from Neutral at Nomura
11/30/20 Baird
Himax price target raised to $11 from $8 at Baird
SMPL Simply Good Foods
$31.21 /

-0.17 (-0.54%)

04/06/21 Credit Suisse
Simply Good Foods initiated with a Neutral at Credit Suisse
03/19/21 Jefferies
Simply Good Foods downgraded to Hold on valuation at Jefferies
03/19/21 Jefferies
Simply Good Foods downgraded to Hold from Buy at Jefferies
02/03/21 DA Davidson
Simply Good Foods downgraded to Neutral from Buy at DA Davidson
MSM MSC Industrial
$91.77 /

-0.065 (-0.07%)

04/05/21 Deutsche Bank
MSC Industrial price target lowered to $89 from $90 at Deutsche Bank
01/07/21 Wells Fargo
MSC Industrial price target raised to $90 from $80 at Wells Fargo
12/31/20 William Blair
Azek, Trex among Blair's top Specialty Distribution ideas for 2021
12/16/20 Deutsche Bank
MSC Industrial price target raised to $92 from $75 at Deutsche Bank
RPM RPM
$94.30 /

+0.21 (+0.22%)

03/04/21 Vertical Research
RPM upgraded to Buy from Hold at Vertical Research
01/08/21 RBC Capital
RPM downgraded to Sector Perform from Outperform at RBC Capital
01/07/21 BMO Capital
RPM price target raised to $113 from $109 at BMO Capital
12/14/20 Morgan Stanley
RPM downgraded to Equal Weight from Overweight at Morgan Stanley
FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

04/07/21 Mizuho
Mizuho downgrades FibroGen to Neutral on 'higher risk and uncertainty'
04/07/21 Mizuho
FibroGen downgraded to Neutral from Buy at Mizuho
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
04/07/21 H.C. Wainwright
FibroGen downgraded to Neutral from Buy at H.C. Wainwright
FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
UPST Upstart
$143.99 /

+3.03 (+2.15%)

03/22/21 Barclays
Upstart price target raised to $110 from $58 at Barclays
03/18/21 BofA
Upstart upgraded to Buy on accelerating growth at BofA
03/18/21 BofA
Upstart upgraded to Buy from Neutral at BofA
03/18/21
Fly Intel: Top five analyst upgrades
UPST Upstart
$143.99 /

+3.03 (+2.15%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

SMPL Simply Good Foods
$31.21 /

-0.17 (-0.54%)

RPM RPM
$94.30 /

+0.21 (+0.22%)

MSM MSC Industrial
$91.77 /

-0.065 (-0.07%)

HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

HIMX Himax
$14.44 /

+0.25 (+1.76%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

  • 09
    Apr
  • 07
    Apr
  • 16
    Dec
  • 27
    May
HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

UPST Upstart
$143.99 /

+3.03 (+2.15%)

TMDX TransMedics
$34.41 /

+0.1 (+0.29%)

SMPL Simply Good Foods
$31.21 /

-0.17 (-0.54%)

RPM RPM
$94.30 /

+0.21 (+0.22%)

HIMX Himax
$14.44 /

+0.25 (+1.76%)

FIXX Homology Medicines
$9.30 /

-0.34 (-3.53%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

CAHC CA Healthcare Acquisition
$9.65 /

+ (+0.00%)

UPST Upstart
$143.99 /

+3.03 (+2.15%)

HYLN Hyliion Holdings
$10.86 /

+0.11 (+1.02%)

HIMX Himax
$14.44 /

+0.25 (+1.76%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

Downgrade
Mizuho downgrades FibroGen to Neutral on 'higher risk and uncertainty' » 06:39
04/07/21
04/07
06:39
04/07/21
06:39
FGEN

FibroGen

$34.61 /

-0.93 (-2.62%)

Mizuho analyst Difei Yang…

Mizuho analyst Difei Yang downgraded FibroGen to Neutral from Buy with a price target of $29, down from $72. The stock in premarket trading is down 29%, or $9.91, to $24.73. The analyst sees "higher risk and uncertainty" around timelines to regulatory approvals following the clarification of previously disclosed cardiovascular safety analyses on roxadustat. Clinical data previously shared with the scientific and investment community included post-hoc adjustments resulting in more favorable safety data, Yang tells investors in a research note. While the new data presented using pre-specified criteria still support the benefit/risk profile of roxadustat, the news creates higher risk in the near term, and uncertainty around timelines to potential approval, says the analyst.

ShowHide Related Items >><<
FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

04/07/21 Mizuho
FibroGen downgraded to Neutral from Buy at Mizuho
04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
04/07/21 H.C. Wainwright
FibroGen downgraded to Neutral from Buy at H.C. Wainwright
04/07/21 JPMorgan
Vifor Pharma upgraded to Neutral from Underweight at JPMorgan
FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

Downgrade
FibroGen downgraded to Neutral from Buy at Mizuho » 06:30
04/07/21
04/07
06:30
04/07/21
06:30
FGEN

FibroGen

$34.61 /

-0.93 (-2.62%)

Mizuho analyst Difei Yang…

Mizuho analyst Difei Yang downgraded FibroGen to Neutral from Buy with a $29 price target.

ShowHide Related Items >><<
FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
04/07/21 H.C. Wainwright
FibroGen downgraded to Neutral from Buy at H.C. Wainwright
04/07/21 JPMorgan
Vifor Pharma upgraded to Neutral from Underweight at JPMorgan
04/07/21 Piper Sandler
Piper 'incrementally positive' on Akebia after 'surprising' FibroGen update
FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

Recommendations
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi » 06:17
04/07/21
04/07
06:17
04/07/21
06:17
AZN

AstraZeneca

$49.22 /

-0.32 (-0.65%)

, FGEN

FibroGen

$34.61 /

-0.93 (-2.62%)

The re-analysis and…

The re-analysis and restatement of the cardiovascular safety data on roxadustat by AstraZeneca (AZN) partner FibroGen (FGEN) "creates a bad optic but ultimately has little impact" on AstraZeneca forecasts or the investment thesis, Citi analyst Andrew Baum tells investors in a research note. The analyst notes that his roxadustat forecasts at $1.3B in 2030 have always remained well below a declining consensus. Baum keeps a Buy rating on AstraZeneca.

ShowHide Related Items >><<
FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

AZN AstraZeneca
$49.22 /

-0.32 (-0.65%)

AZN AstraZeneca
$49.22 /

-0.32 (-0.65%)

03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
03/16/21
Fly Intel: Top five analyst upgrades
FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

04/07/21 H.C. Wainwright
FibroGen downgraded to Neutral from Buy at H.C. Wainwright
04/07/21 JPMorgan
Vifor Pharma upgraded to Neutral from Underweight at JPMorgan
04/07/21 Piper Sandler
Piper 'incrementally positive' on Akebia after 'surprising' FibroGen update
03/31/21 BofA
BofA upgrades FibroGen to Buy, sees roxadustat approval being 'most likely'
FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

AZN AstraZeneca
$49.22 /

-0.32 (-0.65%)

AZN AstraZeneca
$49.22 /

-0.32 (-0.65%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

AZN AstraZeneca
$49.22 /

-0.32 (-0.65%)

FGEN FibroGen
$34.61 /

-0.93 (-2.62%)

AZN AstraZeneca
$49.22 /

-0.32 (-0.65%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.